

Supplementary data

Table S1: Antibiotics susceptibility test to evaluate the MDR profile of *E. coli*, *K. aerogenes*, and *P. aeruginosa*.

Bacterial Species	<i>Escherichia coli</i>		<i>Klebsiella aerogenes</i>		<i>Pseudomonas aeruginosa</i>	
Antibiotics and Disk content	Zone of Inhibition in mm	Antibiotics susceptibility interpretation*	Zone of Inhibition in mm	Antibiotics susceptibility interpretation*	Zone of Inhibition in mm	Antibiotics susceptibility interpretation*
Ampicillin (10 µg)	6±0.5	R	8±0.1	R	6±0.2	R
Ampicillin – Sulbactam (10 µg-10 µg)	13±0.3	I	14±0.3	I	15±0.3	I
Amoxycyllin-Clavulanate (20 µg-10 µg)	6±0.4	R	12±0.4	R	6±0.2	R
Cephalothin (30 µg)	6±0.2	R	12±0.3	R	6±0.3	R
Cefuroxime (30 µg)	6±0.3	R	13±0.3	R	6±0.3	R
Ceftriaxone (10 µg)	10±0.5	R	19±0.5	R	6±0.3	R
Cefoperazone (75 µg)	10±0.3	R	17±0.6	I	6±0.2	R
Cefoxitin (30 µg)	22±0.4	S	18±0.2	I	6±0.1	R
Cefixime (30 µg)	12±0.6	R	14±0.3	R	6±0.3	R
Cefotaxime (30 µg)	12±0.4	I	13±0.6	I	10±0.2	R
Cefotaxime - Clavulanate (30 µg- 10 µg)	19±0.3	R	19±0.7	R	10±0.4	R
Ceftazidime (30 µg)	16±0.3	R	17±0.2	R	6±0.3	R
Cefepime (30 µg)	17±0.3	R	20±0.6	I	6±0.3	R
Piperacillin - Tazobactam (100 µg-10 µg)	22±0.3	S	24±0.5	S	16±0.6	I
Trimethoprim-Sulfamethoxazole (1.25 µg- 23.75 µg)	26±0.5	S	26±0.1	S	6±0.2	R
Ciprofloxacin (5 µg)	8±0.5	R	26±0.2	S	6±0.2	R
Levofloxacin (5 µg)	11±0.4	R	26±0.3	S	12±0.3	R
Chloramphenicol (30 µg)	23±0.4	S	23±0.3	S	6±0.1	R
Imipenem (10 µg)	26±0.6	S	18±0.3	R	15±0.3	R

Meropenem (10 µg)	26±0.3	S	25±0.5	I	13±0.5	R
Tigecycline (15 µg)	19±0.2	S	20±0.4	S	18±0.5	S
Polymyxin B (300 Units)	15±0.7	S	13±0.3	S	19±0.5	S
Colistin (10 µg)	15±0.3	S	12±0.2	S	19±0.4	S
Amikacin (30 µg)	20±0.5	S	16±0.4	I	6±0.2	R
Gentamicin (10 µg)	14±0.3	I	15±0.5	I	6±0.3	R
Tobramycin (10 µg)	16±0.4	S	16±0.2	I	6±0.3	R
Doxycycline (30 µg)	6±0.2	R	19±0.1	S	16±0.5	I
Tetracycline (30 µg)	NA	NA	20±0.2	S	NA	NA
Minocycline (30 µg)	NA	NA	16±0.3	S	NA	NA
Clarithromycin (15 µg)	6±0.1	R	6±0.3	R	6±0.1	R
Erythromycin (15 µg)	6±0.3	R	10±0.3	R	6±0.2	R
Fusidic acid (10 µg)	NA	NA	6±0.3	6	6±0.3	R
Fosfomycin (200 µg)	NA	NA	14±0.7	R	NA	NA
Quinupristin - Dalfopristin (15 µg-15 µg)	NA	NA	6±0.6	R	6±0.2	R
Aztreonam (15 µg)	6±0.3	R	32±0.5	S	6±0.2	R

All experiments were performed in triplicate

R: resistant, I: intermediate, S: susceptible, NA: Not performed

*The antibiotics susceptibility interpretation was based on CLSI guideline-2022 (<https://clsi.org/>)




Figure S1: Images of antimicrobial susceptibility test performed to evaluate the MDR profile of *E. coli*.




Figure S2: Images of antimicrobial susceptibility test performed to evaluate the MDR profile of *K. aerogenes*.




Figure S3: Images of antimicrobial susceptibility test performed to evaluate the MDR profile of *P. aeruginosa*.




Figure S4: The E-test performed to evaluate the MDR profile of (A) *P. aeruginosa*, (B) *K. aerogenes*, and (C) *E. coli*. All strains are extended spectrum beta-lactamase (ESBL) and metallo beta-lactamase (MBL).